Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nkarta Inc (NKTX)

Nkarta Inc (NKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END

ONCY : 1.0312 (+0.12%)
ONC.TO : 1.42 (+0.71%)
AMGN : 333.62 (+0.70%)
AMAM : 28.00 (+0.07%)
ELEV : 2.63 (-0.38%)
NKTX : 6.24 (+0.48%)
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

/PRNewswire/ -- Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq:...

NKTX : 6.24 (+0.48%)
Why Shares of Nkarta Are Slumping Tuesday

The pharmaceutical stock dropped after announcing so-so clinical trial results.

CRSP : 54.95 (+0.71%)
NKTX : 6.24 (+0.48%)
Nkarta Announces Key Senior Leadership Team Appointments

Ralph Brandenberger, PhD, promoted to Chief Technical OfficerYvonne Li, MBA, promoted to Chief Administrative OfficerEvolution of Nkarta leadership team to...

NKTX : 6.24 (+0.48%)
Nkarta to Participate at Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

NKTX : 6.24 (+0.48%)
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development

SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing...

NKTX : 6.24 (+0.48%)
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights

Positive preliminary data reported from NKX101 Phase 1 study in patients with relapsed / refractory AML; 3 of 5 patients treated with a 3-dose regimen of...

NKTX : 6.24 (+0.48%)
2 Red-Hot Stocks That Soared More Than 60% in April

Could these be the next big meme stocks?

NKTX : 6.24 (+0.48%)
RDBX : 1.6500 (-52.86%)
Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?

CEO Vas Narasimhan is seeking acquisitions under $2 billion.

NVS : 108.15 (+1.90%)
NKTX : 6.24 (+0.48%)
DICE : 47.55 (+0.06%)
IMCR : 38.49 (-3.24%)
Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

NKTX : 6.24 (+0.48%)

Barchart Exclusives

Up 121% Since May, What's Behind the Surge in this Penny Stock?
BuzzFeed is a beaten-down tech stock that has gained traction in recent months as several high-profile investors have taken a stake in the media company. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar